Available influenza vaccines: Immunization strategies, history and new tools for fighting the disease

Journal of Preventive Medicine and Hygiene

Volumn 57, Issue 1, 2016, Pages E41-E46

  Barberis, I ^a   Martini, M ^a   Iavarone, F ^a   Orsi, A ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cost effectiveness; Immunization strategies; Influenza vaccines; Quadrivalent influenza vaccine

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; EUROPE; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; ITALY; MORBIDITY; MORTALITY; NONHUMAN; PUBLIC HEALTH SERVICE; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 84979209072     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parodi V, de Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implication for the elderly. Drugs Aging 2011;1;28:93-106.
2. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 2013;12:1085-94.
3. Wood JM, Williams MS. History of Inactivated Influenza vaccines. In: Textbook of Influenza. Oxford: Blackwell Science 1998, pp. 317-23.
4. de Florentiis D, Parodi V, Orsi, Rossi A, Altomonte F, Canepa P, Ceravolo A, Valle L, Zancolli M, Piccotti E, Renna S, Macrina G, Martini M, Durando P, Padrone D, Moscatelli P, Orengo G, Icardi G, Ansaldi F. Impact of influenza during the post-pandemic season: epidemiological picture from syndromic and virological surveillance. J Prev Med Hyg 2011;52:134-6.
5. Crovari P, Alberti M, Alicino C. History and evolution of influenza vaccines. J Prev Med Hyg 2011;52:91-4.
6. Haaheim LR, Madhun AS, Cox R. Pandemic influenza vaccines - the challenges. Viruses 2009;1:1089-109.
7. Treanor JJ. Prospects for broadly protective influenza vaccines. Vaccine 2015;33(Suppl 4):D39-45.
8. Gasparini R, Amicizia D, Lai PL, Panatto D. Live attenuated influenza vaccine. J Prev Med Hyg 2011;52:95-101.
9. Sridhar S, Brokstad KA, Cox RJ. Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines. Vaccines 2015;3:373-89.
10. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination- inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008;26:1525-9.
11. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in helderly subjects, immunized for three consecutive influenza Seasons. Vaccine 1999;17:99-104.
12. Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A. An MF59-adjuvanted inactivated vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006;24:3063-5.
13. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, Podda A. Increased immunogenicity of the MF59- adjuvanted vaccine compared to a conventional vaccine in elderly subjects. Eur J Epidemiol 2001;17:135-40.
14. Arakane R, Annaka R, Takahama A, Ishida K, Yoshiike M, Nakayama T, Takeshita F. Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: a randomized controlled phase III study. Vaccine 2015;33:6650-8.
15. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.
16. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM; American Heart Association; American College of Cardiology; American Association of Cardiovascular and Pulmonary Rehabilitation; American Association of Critical Care Nurses; American Association of Heart Failure Nurses; American Diabetes Association; Association of Black Cardiologists, Inc; Heart Failure Society of America; Preventive Cardiovascular Nurses Association; American Academy of Nurse Practitioners; Centers for Disease Control and Prevention and the Advisory Committee on Immunization. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol 2006;48:1498-502. Erratum in: J Am Coll Cardiol 2006 Dec.
17. Kobashigawa, T, Inoue E, Tanaka E, Momohara S, Yamanaka H. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol 2013;42:445-50.
18. Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 2015;11:135-45.
19. Baluch A, Pasikhova Y. Influenza vaccination in oncology patients. Curr Infect Dis Rep 2013;15:486-90.
20. Caldeira D, Costa J, Vaz-Carneiro A. Analysis of the Cochrane review: influenza Vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev 2015;5:CD00505. Acta Med Port 2015;28:424-6.
21. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. Am J Transplant 2015;15:2767-75.
22. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK; Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1003-32.
23. Seasonal influenza vaccination recommendations in Europe. Available at: http://ecdc.europa.eu/en/publications/Publications/Seasonal-influenza-vaccination-Europe-2012-13.pdf. [Accessed 18/01/16].
24. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.MMWR Recomm Rep 2010;59:1-62.
25. European Centre for Disease Prevention and Control (ECDC). ECDC scientific advice on seasonal influenza vaccination of children and pregnant women. Stockholm: ECDC 2012. Available at: http://www.ecdc.europa.eu/en/publications/Publications/Seasonal%20influenza%20vaccination%20of%20children%20 and%20pregnant%20women.pdf. [Accessed 18/01/16].
26. European Medicines Agency (EMA). Fluenz influenza vaccine (live attenuated, nasal). Summary of opinion1 (initial authorisation). 21 October 2010.London: EMA 2010.EMA/CHMP/503333/2010.Available from: http://www.ema.europa.eu/docs/en-GB/document- library/Summary-of-opinion-Initial-authorisation/human/001101/WC500098347.pdf [Accessed 18/01/16].
27. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jiménez-Jorge S, Savulescu C, Ciancio BC, Moren A. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One 2011;6:e27622.
28. Kissling E, Valenciano M; I-MOVE case-control studies team. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Euro Surveill 2011;16:pii=19818.
29. Centers for Disease Control and Prevention (CDC). Intensivecare patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009;58:749-52.
30. Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, Matyas BT; California Pandemic (H1N1) Working Group. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis 2011;52:301-12.
31. Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, Belay B, Jain S, Cox C, Kamimoto L, Fiore A, Finelli L, Olsen SJ, Fry AM. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One 2010;5:e9694.
32. Council Recommendation of 22 december 2009 on seasonal influenza vaccination. Official journal of the European Union. Available at: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32009H1019. [Accessed 18/01/16].
33. European Centers for Disease Control and Prevention (ECDC). Seasonal Influenza Vaccination Programme in Italy. Available at: http://ecdc.europa.eu/en/publications/Report%20Assets/seasonal-vaccination-coverage-in-europe-2012-13/Seasonal-Influenza-Vaccination-Programme-Country-Profile-Italy.pdf. [Accessed 18/01/16].
34. Bonanni P, Ferro A, Guerra R, Iannazzo S, Odone A, Pompa MG, Rizzuto E, Signorelli C. Vaccine coverage in Italy and assessment of the 2012-2014 National Immunization Prevention Plan. Epidemiol Prev 2015;39(4 Suppl 1):146-58.
35. Crépey P, de Boer PT, Postma MJ, Pitman R. Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Influenza Other Respir Viruses 2015;9(Suppl 1):39-46.
36. Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, Salamanca de la Cueva I, Cabañas F, Treviño-Garza C, Rodríguez-Weber MA, de la O M, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013;208:544-53.
37. Block SL, Falloon J, Hirschfield JA, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, Salamanca de la Cueva I, Cabañas F, Treviño-Garza C, Rodríguez-Weber MA, de la O M, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis 2012;31:745-51.
38. Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 2013;31:5572-8.
39. Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT. Costeffectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. BMC Infect Dis 2015;15:465.
40. Meier Gregg M, Poulsen Nautrup B. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the UK. J Med Econ 2015;18:746-61.
41. Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother 2014;10:1171-80.
42. Eichner M, Schwehm M, Hain J, Phoff H, Salzberger B, Knuf M, Schmidt-Ott R. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis 2014;14:365.